Genomic Valley Biotech Ltd - 539206 - Fixes Book Closure For AGM
Genomic Valley Biotech Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from 24th December, 2022 to 30th December, 2022 (both days inclusive) for the purpose of 28th Annual General Meeting (AGM) of the Company to be held on December 30, 2022. Genomic Valley Biotech Ltd - 539206 - Board Meeting Outcome for Submission Of Outcomes Of Board Meeting Held On 26Th November, 2022
Outcomes of Board Meeting held on 26th November, 2022 Genomic Valley Biotech Ltd - 539206 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of Newspaper Advertisements of the Extract of Un-Audited Financial Results approved in Board Meeting of the Company held on 12.11.2022 Genomic Valley Biotech Ltd - 539206 - Results- Financial Results For 30/09/2022
Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Genomic Valley Biotech Limited ('Company') in its meeting held today approved the Un-Audited Financial Results (Standalone) of the Company for the Quarter ended 30.09.2022 and year to date from 01.04.2022 to 30.09.2022 as per Indian Accounting Standards (IND-AS) along with the Limited Review Report. Copy of the results along with the Limited Review Report of Statutory Auditors is attached herewith for your perusal. Genomic Valley Biotech Ltd - 539206 - Board Meeting Outcome for Submission Of Outcomes Of Board Meeting And Un-Audited Financial Results For The Quarter Ended 30.09.2022 And Year To Date From 01.04.2022 To 30.09. 2022
Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Genomic Valley Biotech Limited ('Company') in its meeting held today approved the Un-Audited Financial Results (Standalone) of the Company for the Quarter ended 30.09.2022 and year to date from 01.04.2022 to 30.09.2022 as per Indian Accounting Standards (IND-AS) along with the Limited Review Report. Copy of the results along with the Limited Review Report of Statutory Auditors is attached herewith for your perusal. Genomic Valley Biotech Ltd - 539206 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisements published for the Notice of Board Meeting to be held on 12th November, 2022, inter-alia, to consider and approve the Un-Audited Financial Results for the quarter and six months ended 30th September, 2022, in the newspapers, Financial Express (English Edition) and Jansatta (Hindi Edition) on 05th November, 2022. Genomic Valley Biotech Ltd - 539206 - Closure of Trading Window
In pursuant of Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Notice is hereby given that a Meeting of the Board of Directors of the Company is scheduled to be held on Saturday, the 12th November, 2022 at 11:45 A.M. inter-alia, to consider and approve the Un-Audited Financial Results for the quarter and six months ended 30th September, 2022. Pursuant to the Code of Conduct for Prevention of Insider Trading of the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, we would like to inform you that the trading window for the purpose of trading in the securities of the Company by its Designated persons has been closed from 01st October, 2022 till 48 hours of declaration of results i.e. 14th November, 2022 (both days inclusive). Genomic Valley Biotech Ltd - 539206 - Board Meeting Intimation for Considering And Approving Un-Audited Financial Results For The Quarter And Six Months Ended September 30, 2022
Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2022 ,inter alia, to consider and approve Un-Audited Financial Results for the quarter and six months ended September 30, 2022 Genomic Valley Biotech Ltd - 539206 - Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Yogesh AgrawalDesignation :- Managing Director / Whole Time Director Genomic Valley Biotech Ltd - 539206 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate pursuant to Regulation 74 (5) of SEBI (Depositories & Participants) Regulations, 2018 for the quarter ended on 30th September, 2022